



David (Dedi) Meiri, Ph.D  
Head, Laboratory of Cancer Biology and Cannabinoid Research  
Faculty of Biology and Technion Integrated Cancer Center  
Technion-Israel Institute of Technology,  
Haifa 320003, Israel  
Tel: [+972-77-8871680](tel:+972-77-8871680) Tel: [+972-52-5330031](tel:+972-52-5330031)  
Email: [dmeiri@tx.technion.ac.il](mailto:dmeiri@tx.technion.ac.il)  
Tel: +972-77-8871680

May 05, 2017

Jeff Goldstein  
Valley Green Grow, Inc.  
1600 Osgood Street  
N. Andover MA 01845

Dear Jeff,

Thank you for meeting with me at the Technion last month and for hosting me during my recent visit to Boston.

I believe it is important for us to develop a strong relationship between our teams. My team and I are constantly evolving in identifying potential solutions and dealing with a variety of medical conditions which probably will bring us to create more productive future joint collaboration.

In the past two years we succeed to build an excellent team "The Meiri lab" with vast knowledge in biochemistry, plant biology, neurobiology and cancer research. Since formation, we applied state-of-the-art technologies and tools which we believe, placing us as leaders in the field of cannabis research.

Our results reflect our abilities to analyze the cannabis extracts, to demonstrate the antitumor effects and constitute a strong foundation to perform any kind of cannabis research, from basic science to clinical trials. Our abilities and our unique collaborations, placing us in an exclusive position to revolutionize the field of medical cannabis, potentially leading to a dramatic change in the way we comprehend medical cannabis treatment.

I truly believe that with the support and collaboration of Valley Green Grow, Inc, we will achieve these goals and bring a significant change to field of medical cannabis.

As a result of our discussions, we have identified several areas of cooperation:

1. Psoriasis study - we feel that the psoriasis study that you are planning at Sheba offers great promise and we wish to work with you to identify the effective bioactive compounds and develop a pharmaceutical product for patient use. We agree with you that basic research supports further investigation and that if the observed anecdotal reports are confirmed in well-designed clinical trial, development of a new pharmaceutical product for treatment of psoriasis may be possible. We willing to share with you our previous data and work and to consider working on this field together.
2. Additional medical research - we are currently engaged in numerous clinical research projects throughout Israel. The R&D campus with incubator space for startups that is proposed for Osgood Landing is attractive to us and can be used as a site to introduce products into the US markets that result from our collaborative research programs in Israel.

3. Regulatory assessment – we share your interest in developing a product that can be used to evaluate impairment in the workplace or at the roadside. Our work to identify and measure the metabolites of THC following Cannabis use offers the potential to identify the time of use. The meter under development by Lumira which will provide 10 different simultaneous measurements from a sample can be used for addressing this problem.
4. US laboratory - The potential for a campus atmosphere that offers R&D funding, incubator support for start-ups, scalable production and proximity to many potential collaborators in Boston is a powerful plan and we will support it with our knowledge.

We welcome this opportunity to work with you and wish you the best possible outcome at town meeting.

Sincerely,



David Meiri, PhD.

Technion-Israel Institute of Technology